Generic Zecuity Availability
Last updated on Jun 11, 2025.
Zecuity is a brand name of , approved by the FDA in the following formulation(s):
ZECUITY (sumatriptan succinate - system;iontophoresis)
-
Manufacturer: TEVA BRANDED PHARM
Approval date: January 17, 2013
Strength(s): EQ 6.5MG BASE/4HR (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zecuity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Transdermal methods and systems for the delivery of anti-migraine compounds
Patent 7,973,058
Issued: July 5, 2011
Inventor(s): Anderson; Carter R. et al.
Assignee(s): NuPathe, Inc. (Conshohocken, PA)Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
Patent expiration dates:
- April 12, 2027✓
- April 12, 2027
-
Pharmacokinetics of iontophoretic sumatriptan administration
Patent 8,155,737
Issued: April 10, 2012
Inventor(s): Sebree Terri B. & Pierce Mark & "ONeill Carol"
Assignee(s): NuPathe, Inc.Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Patent expiration dates:
- April 12, 2027✓
- April 12, 2027
-
Polyamine enhanced formulations for triptan compound iontophoresis
Patent 8,366,600
Issued: February 5, 2013
Inventor(s): Sebree Terri B. & Horstmann Michael & Sameti Mohammad
Assignee(s): NuPathe Inc.A patch and compositions for iontophoresis of triptan compounds are described.
Patent expiration dates:
- April 21, 2029✓
- April 21, 2029
-
Transdermal methods and systems for the delivery of anti-migraine compounds
Patent 8,470,853
Issued: June 25, 2013
Inventor(s): Anderson Carter R. & Morris Russell L. & Sebree Terri B.
Assignee(s): NuPathe Inc.Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
Patent expiration dates:
- April 12, 2027✓
- April 12, 2027
-
Pharmacokinetics of iontophoretic sumatriptan administration
Patent 8,597,272
Issued: December 3, 2013
Inventor(s): Sebree Terri B. & Pierce Mark & "ONeill Carol"
Assignee(s): Nupathe, Inc.Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Patent expiration dates:
- April 12, 2027✓
- April 12, 2027
-
Electronic control of drug delivery system
Patent 8,983,594
Issued: March 17, 2015
Inventor(s): Saar David & Baudis Bogdan Mariusz & Gupta Rainuka & Kamat Vaishali Vilas & Reich Matthew Kent & Srinivasan Rajagopalan
Assignee(s): NuPathe, Inc.In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.
Patent expiration dates:
- November 19, 2030✓✓
- November 19, 2030
-
Transdermal methods and systems for the delivery of anti-migraine compounds
Patent 9,272,137
Issued: March 1, 2016
Inventor(s): Anderson Carter R. & Morris Russell L. & Sebree Terri B.
Assignee(s): Teva Pharmaceuticals International GmbHIontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
Patent expiration dates:
- September 7, 2027✓
- September 7, 2027
-
User-activated self-contained co-packaged iontophoretic drug delivery system
Patent 9,327,114
Issued: May 3, 2016
Inventor(s): Sebree Terri B. & Stathopulos Robert P. & Vinatoru Mihai A.
Assignee(s): Teva Pharmaceuticals International GmbHA user-activated self-contained co-packaged iontophoretic drug delivery system and method of use for treatment of a subject are described.
Patent expiration dates:
- October 8, 2032✓✓
- October 8, 2032
-
Pharmacokinetics of iontophoretic sumatriptan administration
Patent 9,427,578
Issued: August 30, 2016
Inventor(s): Sebree Terri B. & Pierce Mark & "Oneill Carol"
Assignee(s): Teva Pharmaceuticals International GmbHImproved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Patent expiration dates:
- April 12, 2027✓✓
- April 12, 2027
More about Zecuity (sumatriptan)
- Zecuity consumer information
- Check interactions
- Compare alternatives
- Reviews (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- Breastfeeding
Related treatment guides
Related/similar drugs
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Qulipta
Qulipta is used to help prevent episodic or chronic migraine headaches in adults. Qulipta is an ...
Celebrex
Celebrex is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation. Learn about ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Topamax
Topamax (topiramate) is used to prevent seizures in adults and children and to prevent migraine ...
Verapamil
Verapamil is used to treat hypertension (high blood pressure), angina (chest pain), and certain ...
Metoclopramide
Metoclopramide is used short-term to treat heartburn caused by gastroesophageal reflux. Learn about ...
Celecoxib
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation ...
Topiramate
Learn about topiramate, an anticonvulsant used for seizures, migraine prevention, and weight loss ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.